Solvgen Case Essay

746 Words3 Pages
SolvGen Case Write Up Facts: SolvGen Inc., an SEC registrant, is a pharmaceutical development company. SolvGen entered into a five-year research and development agreement with Careway Pharma Inc. on January 1, 2010. The research and development agreement calls for SolvGen to further develop proprietary instrument systems. In connection with executing the research and development arrangement, SolvGen and Careway also entered into a five-year license and distribution agreement dated January 1, 2010. Under the terms of the research and development agreement, SolvGen retains all intellectual rights to the results of the research and development agreement (even in the event of default by the Company). In connection with this agreement, SolvGen is entitled to the following nonrefundable milestone payments from Careway: 1. Exclusive negotiation payment —$1 million (paid December 1, 2009). 2. Contract signing payment —$2 million (paid January 1, 2010). 3. Commercial launch of instrument system Version 1 —$5 million (paid March 31, 2010, upon commercial launch of the instrument system). 4. Commercial launch of instrument system Version 2 —$5 million (not yet paid). 5. Commercial launch of instrument system Version 3 —$5 million (not yet paid). Issues: -What are the deliverables for the arrangement? -When should the milestone payments received to date be recognized as revenues? -What are the deliverables for the arrangement under IFRS? -When would the milestone payments recognized under International Financial Reporting Standards (IFRS)? Alternatives: - Recognize revenue as cash is received. - Recognize revenue at the inception of the contract - Recognize revenue at the termination of the contract - Recognize revenue as the different versions are launched - allocate the contract consideration awards on a pro-rata basis to the revenue received

More about Solvgen Case Essay

Open Document